Skip to main content

Advertisement

SpringerLink
Log in

Oligometastatic breast cancer

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Metastatic breast cancer (MBC) is considered as incurable. The group of patients with oligometastatic disease (a few metastatic lesions and organs involved) apparently have better prognosis. It is claimed that, these patients could be treated with curative intent, and multidisciplinary aggressive approach should be considered. Despite the lack of strong data it is increasingly accepted in clinical practice. Currently, the appropriate candidate would be young woman with good performance status, low tumour burden with long disease-free interval. Because for them with already favorable nature of their disease, aggressive treatment has greater chances to improve survivals. Local ablative treatment (radiotherapy/surgery) has a crucial role in this setting. Available mainly from retrospective in nature long-term results are encouraging but need confirmation in prospective randomized studies. In this review, I discuss the definition of oligometastatic disease, its nature, currently available data and ongoing prospective randomized trials dedicated to oligometastatic breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–30. https://doi.org/10.1093/annonc/mdv298.

    Article  PubMed  Google Scholar 

  2. Reyes DK, Pienta KJ. The biology of oligometastatic cancer. Oncotarget. 2015;6:8491–524.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, et al. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer. 2007;109:2190–6.

    Article  PubMed  CAS  Google Scholar 

  4. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812–23.

    Article  PubMed  CAS  Google Scholar 

  5. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102:456–63. https://doi.org/10.1093/jnci/djq029.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol. 2002;20:620–3.

    Article  PubMed  Google Scholar 

  7. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging. 2004;31:149–61.

    Article  Google Scholar 

  8. Tan S-H, Wolff AC. Treatment of metastatic breast cancer: chemotherapy. In: Harris JR, Lippmann ME, Morrow M, Osborne CK, editors. Diseases of the breast. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. pp. 877–919.

    Google Scholar 

  9. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1.038 women with metastatic breast cancer. Ann Oncol. 2008;19:2012–9. https://doi.org/10.1093/annonc/mdn424.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. O`Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10:20–9.

    Article  CAS  Google Scholar 

  11. Tomiak E, Piccart M, Mignolet F, Sahmoud T, Paridaens R, Nooy M, et al. Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer. 1996;32A:1876–87.

    Article  PubMed  CAS  Google Scholar 

  12. Hellman S, Weichselbaum RR, Oligometastases. J Clin Oncol. 1995;13:8–10.

    Article  PubMed  CAS  Google Scholar 

  13. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378–82. https://doi.org/10.1038/nrclinonc.2011.44.

    Article  PubMed  CAS  Google Scholar 

  14. Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, et al. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005;104:1158–71.

    Article  PubMed  CAS  Google Scholar 

  15. European School of Oncology (ESO)-MBC Task Force. Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. Breast. 2007;16:9–10.

    Article  Google Scholar 

  16. Thomssen C, Augustin D, Ettl J, Haidinger R, Lück HJ, Lüftner D, et al. ABC3 consensus: assessment by a german group of experts. Breast Care (Basel). 2016;11:61–70. https://doi.org/10.1159/000443515.

    Article  Google Scholar 

  17. Halstead W. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46:1–19.

    Article  Google Scholar 

  18. Keynes SGL. Carcinoma of the breast. Post-Graduate Committee FoM, Dalhousie University. Halifax, ed. The Nova Scotia Medical Bulletin. London: St. Bartholomew`s Hospital, 1956;pp. 162–9.

  19. Fisher B. Laboratory and clinical research in breast cancer—a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980;40:3863–74.

    PubMed  CAS  Google Scholar 

  20. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40:107–11. https://doi.org/10.1093/jjco/hyp167.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, et al. The oligometastatic state—separating truth from wishful thining. Nat Rev Clin Oncol. 2014;11:549–57. https://doi.org/10.1038/nrclinonc.2014.96.

    Article  PubMed  Google Scholar 

  22. Arthur DW, Vicini FA, Wazer DE, Khan AJ. Short course breast radiotherapy: a comprehensive review of hypofractionation, partial breast, and intra-operative irradiation. Chmura AJ, Salama JK. Stereotactic treatment for oligometastatic breast cancer. 2016. https://doi.org/10.1007/978-3-319-24388-7_29.

  23. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144:27–40. https://doi.org/10.1016/j.cell.2010.11.055.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Korbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell. 2013;152:1126–36.

    Article  CAS  Google Scholar 

  25. Martin E. The New Oxford Dictionary for Scientific Writers and Editors (2 ed.). 2009; Oxford University Press, Oxford.

    Google Scholar 

  26. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983;1:776–86.

    Article  PubMed  CAS  Google Scholar 

  27. Nguyen DH, Truong PT, Walter CV, Hayashi E, Christie JL, Alexander C. Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann Surg Oncol. 2012;19:3028–34. https://doi.org/10.1245/s10434-012-2333-3.

    Article  PubMed  Google Scholar 

  28. Dorn PL, Meriwether A, LeMieux M, Weichselbaum RR, Chmura SJ. Hasan Y. Patterns of distant failure and progression in breast cancer: implications for the treatment of oligometastatic disease. Int J Radiat Oncol. 2011;81:643. https://doi.org/10.1016/j.ijrobp.2011.06.1901.

    Article  Google Scholar 

  29. Bartlett EK, Simmons KD, Wachtel H, Roses RE, Fraker DL, Kelz RR, et al. The rise in metastasectomy across cancer types over the past decade. Cancer. 2015;121:747–57. https://doi.org/10.1002/cncr.29134.

    Article  PubMed  Google Scholar 

  30. Friedel G, Pastorino U, Ginsberg RJ, Goldstraw P, Johnston M, Pass H, et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg. 2002;22:335–44.

    Article  PubMed  Google Scholar 

  31. Pockaj BA, Wasif N, Dueck AC, Wigle DA, Boughey JC, Degnim AC, et al. Metastasectomy and surgical resection of the primary tumour in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol. 2010;17:2419–26. https://doi.org/10.1245/s10434-010-1016-1.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113:37–49.

    Article  PubMed  CAS  Google Scholar 

  33. Lana LA, Natarajan G, Roth JA, Putnam JBJr. Long-term survival after resection of pulmonary metastases from carcinoma of the breast. Ann Thorac Surg. 1992;54:244–7.

    Article  Google Scholar 

  34. Friedel G, Linder A, Toomes H. The significance of prognostic factors for the resection of pulmonary metastases of breast cancer. Thorac Cardiovasc Surg. 1994;42:71–5.

    Article  PubMed  CAS  Google Scholar 

  35. Mimoto R, Kobayashi T, Imawari Y, Kamio M, Kato K, Nogi H, et al. Clinical relevance and low tumour-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy. Breast Cancer Res Treat. 2014;147:317–24. https://doi.org/10.1007/s10549-014-3111-7.

    Article  PubMed  CAS  Google Scholar 

  36. Vlastos G, Smith DL, Singletary SE, Mirza NQ, Tuttle TM, Popat RJ, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol. 2004;11:869–74.

    Article  PubMed  Google Scholar 

  37. Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Vicente V, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy prior to surgery define outcome. Surgery 2012;151:710–16.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010;76:326–32. https://doi.org/10.1016/j.ijrobp.2009.09.042.

    Article  PubMed  Google Scholar 

  39. Navarria P, De Rose F, Ascolese AM. SBRT for lung oligometastases: Who is the perfect candidate? Rep Pract Oncol Radiother. 2015;20:446–53. https://doi.org/10.1016/j.rpor.2014.11.005.

    Article  PubMed  Google Scholar 

  40. Blumenschein GR, DiStefano A, Caderao J, Fristenberg B, Adams J, Schweichler LH, et al. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. Clin Cancer Res. 1997;3:2633–7.

    PubMed  CAS  Google Scholar 

  41. Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016;122:2242–50. https://doi.org/10.1002/cncr.30058.

    Article  PubMed  CAS  Google Scholar 

  42. de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol. 2014;25:467–71. https://doi.org/10.1093/annonc/mdt537.

    Article  PubMed  Google Scholar 

  43. Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14:e28–37. https://doi.org/10.1016/S1470-2045(12)70510-7.

    Article  PubMed  Google Scholar 

  44. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, et al. An initial report of a radiation dose-escalation trial in patients with 1 to 5 sites of metastatic disease. Clin Cancer Res. 2008;14:5255–9. https://doi.org/10.1158/1078-0432.CCR-08-0358.

    Article  PubMed  CAS  Google Scholar 

  45. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer. 2012;118:2962–70. https://doi.org/10.1002/cncr.26611.

    Article  PubMed  Google Scholar 

  46. Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumours. Radiother Oncol. 2005;77:83–7.

    Article  PubMed  Google Scholar 

  47. Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45:838–47.

    Article  PubMed  Google Scholar 

  48. Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, et al. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis. PLoS One. 2018;13:e0195149. https://doi.org/10.1371/journal.pone.0195149.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112:650–8.

    Article  PubMed  Google Scholar 

  50. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83:878–86. https://doi.org/10.1016/j.ijrobp.2011.08.036.

    Article  PubMed  Google Scholar 

  51. Lee J, Milano MT, Kao J, Chmura S, Salama JK. A multi-institution pooled analysis of oligometastatic patients treated with SBRT. Int J Radiat Oncol Biol Phys. 2014;90:699. https://doi.org/10.1016/j.ijrobp.2014.05.2050.

    Article  Google Scholar 

  52. Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115:601–8. https://doi.org/10.1007/s10549-008-0157-4.

    Article  PubMed  Google Scholar 

  53. Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012;19:218–37. https://doi.org/10.1007/s12282-012-0347-0.

    Article  PubMed  Google Scholar 

  54. Yoo GS, Yu JI, Park W, Huh SJ, Choi DH. Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. Radiat Oncol J. 2015;33:301–9. https://doi.org/10.3857/roj.2015.33.4.301.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, et al. Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. Breast. 2016;26:11–7.

    Article  PubMed  Google Scholar 

  56. Barral M, Auperin A, Hakime A, Cartier V, Tacher V, Otmezguine Y, et al. Percutaneous thermal ablation of breast cancer metastases in oligometastatic patients. Cardiovasc Intervent Radiol. 2016;39:885–93. https://doi.org/10.1007/s00270-016-1301-x.

    Article  PubMed  CAS  Google Scholar 

  57. Available on. www.clinicaltrials.gov. Accessed 10 August 2018.

  58. Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumours (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012;12:305. https://doi.org/10.1186/1471-2407-12-305.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy. J Clin Oncol. 1996;14:2197–205.

    Article  PubMed  CAS  Google Scholar 

  60. Norton L, Simon R. The Norton–Simon hypothesis revisited. Cancer Treat Rep 1986. 1986;70:163–9.

    PubMed  CAS  Google Scholar 

  61. Frey B, Rubner Y, Wunderlich R, Weiss EM, Pockley AG, Fietkau R, et al. Induction of abscopal anti-tumor immunity and immunogenic tumour cell death by ionizing irradiation—implications for cancer therapies. Curr Med Chem. 2012;19:1751–64.

    Article  PubMed  CAS  Google Scholar 

  62. Aberg T, Malmberg KA, Nilsson B, Nöu E. The effect of metastasectomy: fact or fiction? Ann Thorac Surg. 1980;30:378–84.

    Article  PubMed  CAS  Google Scholar 

  63. Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, et al. MicroRNA Expression Characterizes Oligometastasis(es). PLoS One. 2011;6:e28650. https://doi.org/10.1371/journal.pone.0028650.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Specialist Outpatient Clinic, Warsaw, Poland

    Dorota Kwapisz

Authors
  1. Dorota Kwapisz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dorota Kwapisz.

Ethics declarations

Conflict of interest

Author declares that she has no conflict of interest.

Human and animal rights statement

This article does not contain any studies with human or animal subjects performed by the author.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kwapisz, D. Oligometastatic breast cancer. Breast Cancer 26, 138–146 (2019). https://doi.org/10.1007/s12282-018-0921-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-018-0921-1

Keywords

Search

Navigation